查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1844199

神經血管介入器材市場（按產品類型、適應症、最終用戶和手術類型）—2025 年至 2032 年全球預測

Neurovascular Intervention Devices Market by Product Type, Indication, End User, Procedure Type - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，神經血管介入器材市場將成長至 71.4 億美元，複合年成長率為 6.69%。

主要市場統計數據
基準年2024年 42.5億美元
預計2025年 45.3億美元
預測年份：2032年 71.4億美元
複合年成長率（%） 6.69%

對近期神經血管設備創新、臨床應用的促進因素以及相關人員決策的策略考量進行清晰且引人入勝的定位

在設備工程、影像學和急性護理途徑融合發展的推動下，神經血管介入器材領域正在快速發展。過去幾年，臨床醫生和器械開發者已從漸進式改進轉向平台級創新，這些創新正在徹底改變複雜腦血管疾病的診斷、治療和管理方式。這種轉變使得相關人員不僅需要了解產品層面的差異化因素，還需要了解手術流程、報銷動態和照護環境偏好如何相互作用，進而影響設備的採用和療效。

本執行摘要概述了神經血管領域及其相關領域的製造商、臨床領導者和投資者面臨的跨領域趨勢和策略要務。本書將諸如血流導流材料和血栓除去裝置輸送能力的提升等技術進步，與不斷發展的手術方法和付款人考量因素相結合。本書旨在透過重點介紹臨床應用的促進因素以及跨產品類型和適應症的競爭格局，為決策者提供清晰、可行的觀點，以支持其優先考慮研發、上市和夥伴關係策略。

在以下章節中，分析著重於實際意義，平衡技術細節和商業性背景，以便將見解快速轉化為產業計畫和資源分配。

材料科學、成像整合和不斷發展的護理服務模式的突破如何重塑神經血管護理中的設備採用和臨床路徑

神經血管器械領域正在經歷一場變革性的轉變，其影響已超越器械層面的改進，涵蓋操作模式和醫療服務模式。材料科學的突破和精妙的設計正在提升器械的功效和安全性，使臨床醫生能夠處理以往無法治療的解剖結構和複雜的病變形態。同時，增強的影像整合和導航系統正在縮短手術時間並提高器械部署的準確性。

隨著手術成功率和操作人員熟練程度的提高，新的治療途徑不斷湧現，包括在門診手術環境中的推廣應用，以及簡化分診和治療的多學科卒中網路的建立。強調基於價值的照護和結果報告，進一步強化了這種系統性轉變，從而獎勵人們採用能夠顯著減少併發症、再入院率和長期殘疾的設備和手術方法。因此，那些將產品開發與可衡量的臨床結果和簡化的工作流程相結合的公司將佔據更有利的地位。

最後，器械製造商和臨床中心之間的合作模式正在不斷發展，以加速真實世界證據的生成和器械的迭代改進。整合上市後監測、註冊登記和付款人參與的策略夥伴關係正成為商業化策略的重要組成部分，重塑創新從監管核准到常規臨床實踐的進程。

評估新關稅政策對神經血管設備相關人員的供應鏈、採購決策和商業化策略的實際影響

2025年，美國將對某些醫療設備組件和成品徵收關稅，這為神經血管器械相關人員的採購和供應鏈帶來了新的複雜性。擁有全球製造地的製造商被迫重新評估籌資策略和成本結構，以緩解利潤下滑並保持價格競爭力。同時，醫療系統和集團採購組織內的採購團隊正在權衡短期成本成長與長期臨床價值之間的利弊，尤其關注那些能夠顯著縮短手術時間、降低併發症發生率或減少後續護理需求的器械。

立即採取的應對措施包括重新評估供應商契約，強調近岸外包和區域製造夥伴關係，並在合約彈性和付款方動態允許的情況下選擇性地重新定價產品。在某些情況下，開發商正在加快對設計簡化和組件整合的投資，以減少受關稅衝擊的投入。同時，臨床醫生和醫院管理人員專注於保持診療的連續性，並確保獲得一流的醫療設備。因此，策略性地傳達健康經濟效益和比較臨床結果以抵消採購壓力變得更加重要。

隨著關稅相關成本壓力持續存在，那些能夠證明總護理成本效益、確保供應鏈韌性、並根據不斷變化的採購框架調整商業策略的機構將佔據優勢。透明的成本效益證據和靈活的分銷協議對於在貿易條件變化的情況下保持市場進入至關重要。

綜合細分洞察揭示了產品類型、臨床指徵、醫療保健環境和程序類型如何推動採用動態和商業性優先級

市場區隔框架透過整合產品、適應症、最終使用者和程序觀點提供具體見解。根據產品類型，栓塞劑、流量轉向器、微導管、神經血管線圈、支架和血栓切除裝置等設備類別各自表現出不同的臨床和商業性動態。在栓塞劑中，液體和顆粒栓塞劑之間的差異會影響程序、儲存和處理注意事項以及臨床使用案例。流量轉向器在管道栓塞裝置和超越流量轉向器等設備中呈現出差異化的價值提案，輸送能力、徑向力和內皮化特徵的差異會影響臨床醫生的偏好。微導管塗層，無論是親水性或聚合物基，都會改變操作員所依賴的觸覺和導航特性。支架平台、球囊展開和自膨脹在病灶準備和展開工作流程方面有所不同，血栓切除策略分為抽吸器和支架回收器。

從適應症角度來看，動脈瘤治療、動靜脈畸形治療和急性缺血性中風治療對設備性能、庫存管理和手術團隊組成提出了不同的要求。最終使用者按門診、診所和醫院環境進行細分，進一步改變了部署時間表和採購行為。門診中心通常優先考慮精簡、高通量的解決方案，而醫院則重視多功能性和全面的庫存，以支援複雜的病例。最後，栓塞、血流改道和血栓切除術等手術類型的細分揭示了手術量、操作人員專業知識和病例複雜性如何相互作用，從而決定設備組合和耗材的使用。

總的來說，這些細分強調了根據每個臨床和操作環境的細微需求客製化產品設計、培訓計劃和商業性通訊的重要性。

比較區​​域動態，揭示法規環境、付款人結構和臨床網路如何推動差異化採用和商業化路徑

神經血管介入治療的區域動態反映了法律規範、衛生系統架構和臨床實踐模式的差異。在美洲，先進的卒中系統和強大的三級醫療網路促進了血管內介入治療方案的快速應用，重點是整合院前分診和院間轉運通訊協定，以最大限度地實現及時干預。該地區通常為新醫療設備的早期應用提供了良好的環境，前提是這些醫療器材有強力的臨床證據和經濟可行性支持，並且支付方在製定承保決策時擴大審查比較結果。

在歐洲、中東和非洲，某些市場的監管環境趨於協調，而其他市場的准入和報銷政策則呈現多樣性。臨床醫生網路和卓越中心 (COE) 模式推動了主要都市區的採用，而更廣泛的人口採用則取決於當地採購慣例和報銷政策的協調。部分歐洲、中東和非洲市場的資本預算限制正在推動基於價值的採購和長期醫療成本分攤的討論，為能夠顯著減輕整體護理負擔的醫療設備創造了投資機會。

亞太地區正見證大批量生產設施的快速應用，同時國內器械開發生態系統也在不斷發展。該地區的醫療保健系統正在投資卒中基礎設施和先進的介入神經放射學培訓，以支援現有和新型器械類別的擴展。然而，分散的監管途徑和多樣化的支付方安排使得打入市場策略需要細緻入微，包括與本地夥伴關係建立合作夥伴關係以及產生針對特定地區的臨床證據。在所有地區，供應鏈的韌性、監管準備度以及針對當地實踐模式的客製化證據都是成功進入市場的關鍵因素。

透過臨床證據、製造敏捷性以及與醫療保健系統優先事項的策略一致性來決定市場領導地位的動態和協作動態

神經血管介入領域的競爭態勢由眾多成熟的器材創新者、新興的專業公司以及垂直整合的醫療科技公司共同塑造。規模較大的公司通常會大力投資於器械的迭代改進、強大的臨床試驗項目以及廣泛的培訓計劃，以縮短操作人員的學習曲線並加速機構的採用。同時，規模較小、更敏捷的公司則經常推出差異化的材料和給藥機制，尤其是在細分的解剖結構和手術流程中，這些領域的漸進式改進可以帶來顯著的臨床效益，挑戰現有公司並促進品類擴張。

設備開發商與臨床卓越中心之間的夥伴關係是產生真實世界證據並根據操作回饋最佳化設備迭代的常見策略方法。此類合作模式透過累積本地專業知識並產生支付方參與所需的結果數據，有助於加速臨床應用。此外，那些將商業策略與醫療系統優先事項（例如縮短住院時間、降低併發症發生率以及實現當日手術）相結合的公司更有可能獲得處方集的收錄並獲得有利的採購條款。

強大的智慧財產權、擴充性的生產能力和多元化的供應鏈仍然是至關重要的競爭優勢。持續投資於上市後監測、教育計畫和全面臨床支援的公司，能夠更好地維持市場佔有率，並拓展至鄰近的適應症和地區。實力雄厚的公司將技術力與在監管、報銷和臨床應用管道的營運能力相結合。

可行的策略和營運建議，用於協調產品設計、證據生成和商業性執行，以確保永續的採用和價值

產業領導者應採取協調產品開發、證據產生和商業性執行的策略，以加速應用並維護其市場地位。優先考慮能夠最佳化交付能力和手術效率的設計方案，這將引起那些專注於縮短手術時間和提高安全性的臨床醫生的共鳴。同時，投資於可靠的真實世界證據項目和衛生經濟學分析對於說服採購委員會和付款人相信設備選擇將顯著降低醫療保健總成本至關重要。

在營運方面，企業應透過多元化採購、探索區域製造夥伴關係以及在可行的情況下簡化材料清單來提升供應鏈的韌性，以減輕貿易波動的影響。在商業性，根據最終用戶細分客製化培訓和支援模式，並針對門診中心、診所和醫院採取差異化方法，可以在確保服務品質的同時加快技術應用。與領先的臨床中心建立策略夥伴關係，共同開發最佳實踐方案和案例庫，縮短了學習曲線，並在更廣泛的臨床醫生群體中建立了信任。

最後，領導團隊必須在定價和合約模式上保持彈性，以適應不同的報銷環境和採購流程。當結果資料支援基於價值的合約、風險分擔安排和捆綁支付模式時，應考慮此類結構。將臨床、營運和商業優先事項整合到一個連貫的計劃中，使組織能夠將創新轉化為永續的臨床和財務價值。

一種透明、多方法的調查方法，結合專家訪談、文獻綜合和情境測試，提供可靠、可行的見解

本分析所依據的調查方法整合了多種定性和定量分析方法，以確保研究的嚴謹性和有效性。主要資訊包括與臨床專家、採購主管和行業高管進行結構化訪談，以深入了解流程、應用促進因素和採購決策標準。這些訪談與同行評審的臨床文獻、監管文件和會議記錄相結合，以檢驗性能聲明並確定新興的臨床共識。

補充性二手研究檢視了器械設計趨勢、製造考量和供應鏈動態，並著眼於貿易政策變化和區域監管發展。該調查方法還結合了對報銷和衛生經濟學文獻的評估，以建構採用獎勵和付款人觀點。資料整合強調跨來源的交叉檢驗，資訊來源結果和專家意見，並提供關鍵結論可信度的透明度。

在適當的情況下，我們會運用情境分析來探討政策變化、供應鏈中斷以及不同醫療機構採用率差異的影響。在整個過程中，該方法優先考慮切實可行的洞察，將技術設備屬性與對臨床醫生、醫院管理人員和投資者至關重要的營運和商業成果聯繫起來。

將設備創新、證據策略和營運彈性連結起來的結論性綜合是永續影響和競爭優勢的關鍵。

摘要，神經血管介入領域正從漸進式改善到變革性創新轉型，這些創新正在再形成臨床路徑、採購行為和競爭動態。器械設計和手術技術的進步正在拓展治療可能性並改善療效，但成功的商業化越來越需要整合策略。 2025年的關稅格局強調了敏捷籌資策略和更清晰地展示總醫療成本效益的必要性，以維持市場准入和臨床醫生的採用。

針對產品細微差別、適應症要求、最終用戶偏好和流程環境，量身定做的細分市場方法對於確定投資優先事項和提案引人注目的價值主張至關重要。差異化的地域策略同樣重要，因為監管、報銷和醫療保健交付框架將對採用的時間和規模產生重大影響。將卓越技術與嚴格的循證計劃、適應性強的商業模式和富有韌性的業務營運相結合的公司將最有可能佔據主導。

最終，從創新到標準化治療的路徑取決於臨床、商業和營運領域的全面執行。積極主動協調這些要素的相關人員將獲得最大價值，並為改善神經血管治療的患者預後做出有意義的貢獻。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 使用血流改道裝置治療複雜顱內動脈瘤可提高長期阻塞率
  • 可生物分解栓塞材料的進展降低慢性發炎風險並促進血管重塑
  • 即時機器人輔助神經血管導航系統的整合提高了手術的精確度和安全性
  • 開發下一代薄壁支架，以改善血管相容性並減少血栓形成
  • 實施人工智慧驅動的影像分析以最佳化血管內手術計劃
  • 對於具有改進扭矩控制的微導管的需求日益成長，以便有效地導航曲折的腦血管。
  • 擴展的混合手術室套件結合了 CT血管造影術和螢光透視技術，以簡化神經介入治療
  • 微創液體栓塞劑的發展，可實現低風險的標靶血管閉塞

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章神經血管介入器材市場（依產品類型）

  • 栓塞劑
    • 液體栓子
    • 顆粒栓塞
  • 流量轉向器
    • 管道栓塞裝置
    • 超越流量轉向器
  • 微導管
    • 親水塗層
    • 聚合物塗層
  • 神經血管線圈
    • 可拆卸線圈
    • 可推線圈
  • 支架
    • 氣球安裝
    • 自膨脹
  • 血栓除去裝置
    • 吸力裝置
    • 支架取栓器

第9章神經血管介入器材市場（按適應症）

  • 動脈瘤
  • 動靜脈畸形
  • 中風

第 10 章神經血管介入器材市場（依最終用戶）

  • 門診中心
  • 診所
  • 醫院

第 11 章神經血管介入器械市場（依手術類型）

  • 栓塞治療
  • 流量轉換
  • 血栓切除術

第12章神經血管介入器材市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章神經血管介入器材市場（依類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章神經血管介入器材市場（依國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Stryker Corporation
    • Medtronic plc
    • Johnson & Johnson
    • Penumbra, Inc.
    • Boston Scientific Corporation
    • Terumo Corporation
    • Becton, Dickinson and Company
    • MicroPort Scientific Corporation
    • MicroVention, Inc.
    • Kaneka Corporation
Product Code: MRR-ED54C46E8FA1

The Neurovascular Intervention Devices Market is projected to grow by USD 7.14 billion at a CAGR of 6.69% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.25 billion
Estimated Year [2025] USD 4.53 billion
Forecast Year [2032] USD 7.14 billion
CAGR (%) 6.69%

A clear and engaging orientation to recent neurovascular device innovations, clinical adoption drivers, and strategic considerations shaping stakeholder decisions

The landscape of neurovascular intervention devices is evolving rapidly, driven by convergent advances in device engineering, imaging, and acute care pathways. Over the last several years clinicians and device developers have moved from incremental improvements toward platform-level innovations that change how complex cerebrovascular diseases are diagnosed, treated, and managed. These shifts have heightened the imperative for stakeholders to understand not only product-level differentiators but also how procedural workflows, reimbursement dynamics, and care setting preferences interact to shape adoption and outcomes.

This executive summary synthesizes cross-cutting trends and strategic imperatives for manufacturers, clinical leaders, and investors who operate in or adjacent to the neurovascular domain. It situates technology progress-such as enhancements in flow diversion materials and thrombectomy device deliverability-alongside evolving procedural approaches and payer considerations. By clarifying the drivers of clinical adoption and the competitive tensions across product categories and indications, the narrative aims to equip decision-makers with a clear, actionable perspective that supports prioritization of R&D, go-to-market investments, and partnership strategies.

Throughout the following sections, the analysis maintains an emphasis on practical implications, balancing technical detail with commercial context to facilitate rapid translation of insight into operational planning and resource allocation.

How material science breakthroughs, imaging integration, and evolving care delivery models are reshaping device adoption and clinical pathways in neurovascular care

The neurovascular device landscape is undergoing transformative shifts that extend beyond device-level improvements to encompass procedural paradigms and care delivery models. Material science breakthroughs and refined designs have increased device efficacy and safety profiles, enabling clinicians to tackle previously untreatable anatomies and complex lesion morphologies. Simultaneously, enhanced imaging integration and navigation systems have reduced procedural times and improved the precision of device deployment, which in turn has broadened the pool of eligible patients and increased clinician confidence in advanced interventions.

As procedural success rates and operator familiarity grow, new pathways for care are emerging, including expanded utilization in ambulatory surgical settings and the creation of multidisciplinary stroke networks that streamline triage and treatment. These systemic shifts are reinforced by an emphasis on value-based care and outcomes reporting, which incentivize devices and procedural approaches that demonstrably reduce complications, rehospitalizations, and long-term disability. Consequently, companies that align product development with measurable clinical outcomes and streamlined workflows will be better positioned to gain traction.

Finally, collaboration models between device manufacturers and clinical centers are evolving to accelerate real-world evidence generation and iterative device refinement. Strategic partnerships that integrate post-market surveillance, registries, and payer engagement are becoming essential components of commercialization strategies, reshaping how innovations migrate from regulatory approval to routine clinical practice.

Assessing the practical repercussions of new tariff policies on supply chains, procurement decisions, and commercialization strategies across neurovascular device stakeholders

The introduction of tariffs in 2025 for certain medical device components and finished goods has introduced an additional layer of procurement and supply chain complexity for neurovascular device stakeholders. Manufacturers with global manufacturing footprints have been prompted to reassess sourcing strategies and cost structures to mitigate margin erosion and maintain price competitiveness. In turn, procurement teams within health systems and group purchasing organizations are weighing the trade-offs between short-term cost increases and long-term clinical value, particularly for devices that deliver demonstrable reductions in procedure time, complication rates, or subsequent care requirements.

Immediate responses have included a re-evaluation of supplier contracts, increased emphasis on nearshoring or regional manufacturing partnerships, and selective repricing of products where contractual flexibility and payer dynamics permit. In some cases, developers have accelerated investments in design simplification and component consolidation to reduce exposure to tariffed inputs. Meanwhile, clinicians and hospital administrators are focused on preserving procedural continuity and access to best-in-class devices; therefore, strategic communication of health-economic benefits and comparative clinical outcomes has become more critical to offset procurement pressures.

Looking ahead, sustained tariff-related cost pressures will favor organizations that can demonstrate total cost of care benefits, secure resilient supply chains, and adapt commercial strategies to evolving procurement frameworks. Transparent cost-effectiveness evidence and flexible distribution agreements will be pivotal in maintaining market access under shifting trade conditions.

Integrated segmentation insights that reveal how product types, clinical indications, care settings, and procedure types jointly determine adoption dynamics and commercial priorities

The market segmentation framework yields specific insights when product, indication, end user, and procedure perspectives are integrated. Based on product type, device categories such as embolic agents, flow diverters, microcatheters, neurovascular coils, stents, and thrombectomy devices each present distinct clinical and commercial dynamics. Within embolic agents, the distinctions between liquid embolics and particulate embolics influence procedural technique, storage and handling considerations, and clinical use cases. Flow diverters show differentiated value propositions across devices such as the Pipeline Embolization Device and the Surpass Flow Diverter, where differences in deliverability, radial force, and endothelialization profiles affect clinician preference. Microcatheter coatings, whether hydrophilic or polymer-based, change the tactile and navigational characteristics that operators rely upon, while coil technologies that are detachable versus pushable define different trade-offs in deployment control and repositionability. Stent platforms that are balloon-mounted versus self-expanding present distinct lesion preparation and deployment workflows, and thrombectomy strategies split between aspiration devices and stent retrievers, each with specific procedural success patterns that inform institutional purchasing decisions.

When viewed through the lens of indication, aneurysm treatment pathways, arteriovenous malformation interventions, and acute ischemic stroke care place divergent demands on device performance, inventory management, and procedural team composition. End user segmentation-ambulatory centers, clinics, and hospitals-further modulates adoption timelines and procurement behaviors, with ambulatory centers often prioritizing streamlined, high-throughput solutions and hospitals emphasizing versatility and comprehensive inventory to support complex cases. Finally, procedure type segmentation across embolization, flow diversion, and thrombectomy highlights how procedural volume, operator expertise, and case complexity interact to determine device mix and consumable usage.

Taken together, these segmentation lenses underscore the importance of tailoring product design, training programs, and commercial messaging to the nuanced needs of each clinical and operational context, ensuring that innovations are positioned to overcome adoption barriers and deliver measurable clinical impact.

Comparative regional dynamics revealing how regulatory environments, payer structures, and clinical networks drive differentiated adoption and commercialization pathways

Regional dynamics in neurovascular interventions reflect differences in regulatory frameworks, health system architectures, and patterns of clinical practice. In the Americas, advanced stroke systems and robust tertiary care networks have facilitated rapid uptake of endovascular solutions, with a pronounced emphasis on integrating pre-hospital triage and inter-hospital transfer protocols to maximize timely intervention. This region often serves as an early adopter environment for novel devices when backed by strong clinical evidence and health-economic justification, and payers increasingly scrutinize comparative outcomes as part of coverage decisions.

Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization in certain markets coexists with variable access and reimbursement policies in others. Clinician networks and center-of-excellence models drive adoption in major urban centers, while translation to broader populations depends on local procurement practices and reimbursement alignment. In some EMEA markets, constrained capital budgets emphasize value-based purchasing and long-term cost-of-care arguments, creating opportunities for devices that demonstrably reduce overall treatment burden.

Asia-Pacific exhibits rapid adoption in high-volume centers alongside growing domestic device development ecosystems. Health systems across the region are investing in stroke infrastructure and advanced neurointerventional training, which supports scaling of both established and newer device categories. However, fragmented regulatory pathways and diverse payer arrangements require nuanced market entry strategies, including local partnerships and region-specific clinical evidence generation. Across all regions, supply chain resilience, regulatory readiness, and evidence tailored to local practice patterns are decisive factors in successful market penetration.

Competitive and collaborative dynamics that determine market leadership through clinical evidence, manufacturing agility, and strategic alignment with health system priorities

Competitive dynamics in neurovascular interventions are shaped by a mix of established device innovators, emerging specialized firms, and vertically integrated healthcare technology companies. Leading organizations typically invest heavily in iterative device refinement, robust clinical trial programs, and broad training initiatives that reduce operator learning curves and accelerate institutional adoption. Meanwhile, smaller, agile firms frequently introduce differentiated materials or delivery mechanisms that challenge incumbents and catalyze category expansion, particularly in niche anatomies or procedural workflows where incremental improvements yield outsized clinical benefit.

Partnerships between device developers and clinical centers of excellence are a common strategic approach to generate real-world evidence and optimize device iterations based on procedural feedback. These collaborative models support faster clinical adoption by building local expertise and producing the outcome data required for payer engagement. Additionally, companies that align their commercial strategies with health system priorities-such as reducing length of stay, decreasing complication rates, or enabling same-day procedures-find it easier to secure formulary inclusion and favorable procurement terms.

Intellectual property strength, manufacturing scalability, and supply chain diversification remain decisive competitive levers. Organizations that demonstrate sustained investment in post-market surveillance, education programs, and integrated clinical support are better positioned to retain market share and expand into adjacent indications and geographies. The most resilient players combine technical excellence with operational fluency across regulatory, reimbursement, and clinical adoption channels.

Actionable strategic and operational recommendations for aligning product design, evidence generation, and commercial execution to secure sustainable adoption and value

Industry leaders should adopt a coordinated strategy that aligns product development, evidence generation, and commercial execution to accelerate adoption and defend market position. Prioritizing design choices that optimize deliverability and procedural efficiency will resonate with clinicians focused on reducing procedure time and improving safety outcomes. Concurrently, investing in robust real-world evidence programs and health-economic analyses will be critical to persuade procurement committees and payers that device selection yields measurable reductions in total cost of care.

Operationally, companies should pursue supply chain resilience by diversifying sourcing, exploring regional manufacturing partnerships, and simplifying bill-of-materials where feasible to mitigate exposure to trade fluctuations. Commercially, tailoring training and support models to end user segmentation-differentiating approaches for ambulatory centers, clinics, and hospitals-will help accelerate adoption while maintaining service quality. Strategic partnerships with leading clinical centers to develop best-practice protocols and case libraries will shorten learning curves and build trust among broader clinician cohorts.

Finally, leadership teams must maintain flexibility in pricing and contracting models to accommodate varied reimbursement environments and procurement processes. Value-based contracting, risk-sharing arrangements, and bundled payment models should be explored where outcomes data support such structures. By integrating clinical, operational, and commercial priorities into a single coherent plan, organizations can convert innovation into sustainable clinical and financial value.

A transparent and multi-method research approach that combines expert interviews, literature synthesis, and scenario testing to ensure robust, actionable insights

The research methodology underpinning this analysis integrates multiple qualitative and quantitative approaches to ensure rigour and relevance. Primary inputs include structured interviews with clinical experts, procurement leaders, and industry executives, which provide contextual understanding of procedural workflows, adoption drivers, and purchasing decision criteria. These conversations are triangulated with a review of peer-reviewed clinical literature, regulatory filings, and conference proceedings to validate performance claims and identify emerging clinical consensus.

Complementary secondary research examines device design trends, manufacturing considerations, and supply chain dynamics, with attention to changes in trade policy and regional regulatory developments. The methodology also incorporates an assessment of reimbursement and health-economic literature to frame adoption incentives and payer perspectives. Data synthesis emphasizes cross-validation across sources and a clear delineation between evidence-based findings and expert opinion, with transparency about the level of confidence for key conclusions.

Where appropriate, scenario analysis is used to explore the implications of policy shifts, supply chain disruptions, and differential adoption rates across care settings. Throughout, the approach prioritizes actionable insight, linking technical device characteristics to operational and commercial outcomes that matter to clinicians, hospital executives, and investors.

Concluding synthesis that connects device innovation, evidence strategy, and operational resilience as the keys to sustainable impact and competitive advantage

In summary, the neurovascular intervention space is transitioning from incremental refinements to transformative innovations that reshape clinical pathways, procurement behaviors, and competitive dynamics. Advances in device design and procedural technology are expanding treatment possibilities and improving outcomes, but successful commercialization increasingly requires integrated strategies that align clinical evidence, supply chain resilience, and payer engagement. The 2025 tariff landscape has amplified the need for nimble sourcing strategies and stronger articulation of total cost of care benefits to maintain market access and clinician adoption.

Segmentation-specific approaches-attuned to product nuances, indication requirements, end-user preferences, and procedural contexts-are essential to prioritize investments and craft persuasive value propositions. Regionally differentiated strategies are equally important, as regulatory, reimbursement, and care delivery frameworks materially influence adoption timing and scale. Companies that combine technical excellence with rigorous evidence programs, adaptable commercial models, and resilient operations will be best positioned to lead.

Ultimately, the path from innovation to standard of care depends on deliberate execution across clinical, commercial, and operational domains. Stakeholders who act proactively to align these elements will capture the greatest value and contribute meaningfully to improved patient outcomes in neurovascular care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Adoption of flow diversion devices for complex intracranial aneurysm treatment improving long-term occlusion rates
  • 5.2. Advances in biodegradable embolic materials reducing risk of chronic inflammation and aiding vessel remodeling
  • 5.3. Integration of real-time robotic-assisted neurovascular navigation systems enhancing procedural precision and safety
  • 5.4. Development of next-generation thin-walled stents for improved vessel conformability and reduced thrombogenicity
  • 5.5. Implementation of artificial intelligence-driven imaging analytics for optimized endovascular procedure planning
  • 5.6. Rise in demand for microcatheters with improved torque control to navigate tortuous cerebral vasculature effectively
  • 5.7. Expansion of hybrid operating room suites combining CT angiography and fluoroscopy to streamline neurointerventions
  • 5.8. Growth in minimally invasive liquid embolic agents enabling targeted vascular occlusion with lower risk profiles

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Neurovascular Intervention Devices Market, by Product Type

  • 8.1. Embolic Agents
    • 8.1.1. Liquid Embolics
    • 8.1.2. Particulate Embolics
  • 8.2. Flow Diverters
    • 8.2.1. Pipeline Embolization Device
    • 8.2.2. Surpass Flow Diverter
  • 8.3. Microcatheters
    • 8.3.1. Hydrophilic Coated
    • 8.3.2. Polymer Coated
  • 8.4. Neurovascular Coils
    • 8.4.1. Detachable Coils
    • 8.4.2. Pushable Coils
  • 8.5. Stents
    • 8.5.1. Balloon Mounted
    • 8.5.2. Self Expanding
  • 8.6. Thrombectomy Devices
    • 8.6.1. Aspiration Devices
    • 8.6.2. Stent Retriever

9. Neurovascular Intervention Devices Market, by Indication

  • 9.1. Aneurysm
  • 9.2. Arteriovenous Malformation
  • 9.3. Stroke

10. Neurovascular Intervention Devices Market, by End User

  • 10.1. Ambulatory Centers
  • 10.2. Clinics
  • 10.3. Hospitals

11. Neurovascular Intervention Devices Market, by Procedure Type

  • 11.1. Embolization
  • 11.2. Flow Diversion
  • 11.3. Thrombectomy

12. Neurovascular Intervention Devices Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Neurovascular Intervention Devices Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Neurovascular Intervention Devices Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Stryker Corporation
    • 15.3.2. Medtronic plc
    • 15.3.3. Johnson & Johnson
    • 15.3.4. Penumbra, Inc.
    • 15.3.5. Boston Scientific Corporation
    • 15.3.6. Terumo Corporation
    • 15.3.7. Becton, Dickinson and Company
    • 15.3.8. MicroPort Scientific Corporation
    • 15.3.9. MicroVention, Inc.
    • 15.3.10. Kaneka Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NEUROVASCULAR INTERVENTION DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. NEUROVASCULAR INTERVENTION DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. NEUROVASCULAR INTERVENTION DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY LIQUID EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PARTICULATE EMBOLICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PIPELINE EMBOLIZATION DEVICE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SURPASS FLOW DIVERTER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HYDROPHILIC COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY POLYMER COATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY DETACHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PUSHABLE COILS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY BALLOON MOUNTED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SELF EXPANDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ASPIRATION DEVICES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENT RETRIEVER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ANEURYSM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY ARTERIOVENOUS MALFORMATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STROKE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY AMBULATORY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERSION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 195. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 196. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 197. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 198. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 199. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 200. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 201. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 202. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 203. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 204. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 205. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 206. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 207. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 208. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 209. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AMERICAS NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 216. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 217. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 218. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 219. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 220. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 221. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 222. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 223. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 224. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 225. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 226. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 227. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 228. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 229. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. NORTH AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 238. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 239. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 240. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 241. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 242. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 243. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 244. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 245. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 246. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 247. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 248. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 249. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 250. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 251. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 252. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 253. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. LATIN AMERICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY EMBOLIC AGENTS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY FLOW DIVERTERS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY MICROCATHETERS, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY NEUROVASCULAR COILS, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY STENTS, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPE, MIDDLE EAST & AFRICA NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY PROCEDURE TYPE, 2025-2032 (USD MILLION)
  • TABLE 277. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE NEUROVASCULAR INTERVENTION DEVICES MARKET SIZE, BY